PepTracker App

We’re live. PepTracker is now available on the App Store. Track your peptides, schedule injections, calculate doses, and log your protocols— all in one place. 📲 apps.apple.com/us/app/peptrac… Coming soon to Android.

@bramk 👀

Peptide journey starting tomorrow

@PeptidePartners love to see it!! chatted with her a months ago, she’s great!

The inventor of SS-31 read our substack article on it. She is a brilliant and modest scientist.

GLP-1s are doing a lot more than suppressing appetite and the data reflects that. This is why tracking your protocol matters.

@Budgetdog_ solid stack!

A lot of people have been asking me about my peptide stack. Here it is: - TB-500 - BPC-157 - MOTS-C - Tru-Niagen - Tesamorelin - CJC-1295 (no DAC) I do a lot more beyond this for health that is critical too. Game changer.

Eli Lilly's orforglipron just got approved as the first GLP-1 pill for weight loss. A lot of people who passed on injections are about to reconsider. The barrier to entry just got a lot lower.

The FDA is expected to lift its ban on injectable peptides from compounding pharmacies. The regulatory tide is finally shifting.

Peptide Sciences, arguably one of the largest research peptide vendors, just announced they’re shutting down. That’s a pretty big deal considering how long they’ve been around. It also likely won’t be the last. As compounding pharmacies gain clearer pathways to prescribe peptides, the old “research peptide” vendor model becomes harder to sustain. A few things worth knowing: - This doesn’t mean peptides are going away - Some gray-market vendors will likely disappear - New ones will also show up quickly When a big vendor disappears, the market doesn’t disappear. It fragments.

If this plays out, we’re entering a more regulated phase of the peptide market…but that doesn’t necessarily make it simpler. Gray markets don’t disappear overnight. They evolve. Access and enforcement often expand at the same time. That increases fragmentation. More vendors. More supply channels. More variability. More room for protocol error. Regulation may improve oversight. It doesn’t remove execution complexity. Access gets attention. Structure determines outcomes.

RFK Jr. was just on Joe Rogan’s podcast and said ~14 peptides currently restricted under the FDA’s Category 2 list could soon be eligible for legal compounding again. If implemented, that would materially EXPAND peptide access in the U.S. Category 2 status currently restricts compounding due to safety concerns. Moving substances to Category 1 would allow regulated U.S. pharmacies to compound them under oversight, potentially reducing reliance on unregulated sourcing. Access expansion changes behavior quickly. If more peptides become legally compoundable, we’ll likely see: - More first-time users - More stacking - Faster experimentation - More telehealth activity But increased availability doesn’t automatically improve outcomes. More compounds in circulation often means: - Overlapping protocols - Escalation mistakes - Inconsistent cycles - Less clarity on what’s actually working Regulatory shifts may improve supply chain oversight. They don’t replace execution discipline. Whether 14 peptides move or not, one variable remains constant: Outcomes depend on structured use. Clear protocols. Intentional dosing. Consistent tracking. If peptide access expands, structured protocol management becomes even more important. That’s exactly why PepTracker exists.

As more GLP-1 options enter the market, oral or injectable, the variable that won’t change is execution. If you’re running a protocol, track it. We built PepTracker for exactly that. apps.apple.com/us/app/peptrac…

The molecule matters. But behavior matters more. Whether it’s: - Injectable semaglutide - Tirzepatide - Retatrutide - Orforglipron The winners will still be the ones who track, escalate intentionally, and stay consistent. That’s the part most headlines miss.

Lilly’s oral GLP-1 (orforglipron) outperformed oral semaglutide in A1C and weight loss in a head-to-head T2D trial published in The Lancet. This is meaningful comparative data. But let’s add some context… 👇

@frankdegods this is actually the perfect analogy

peptides are like claude code for your cells

If your friends aren’t talking about: - Peptides - And how to track them Time to find new friends (and download us)

@jayperedox @julesyoo 👀

100%. We’re currently B2C first with @PepTracker to avoid that early B2B "product tax" and keep our roadmap fast. Got the GLP-1 + peptide adherence loop dialed in organically, and now we're using that exact playbook to pilot with clinics. The consumer wedge has been super helpful as we push more into the B2B side of the market. 🤝

A few years ago, calling yourself a consumer health company in front of VCs was a virtual death sentence... but now, not only is consumer health being taken seriously, there are also some very serious consumer health businesses being built in the wild. This, plus other hot takes from @hollsmaloney, @ryu_alison, @KGSeidensticker and I at the inaugural Stanford Consumer Health Summit: ⚡ It's certainly possible now to build a large business purely based on cash pay + DTC acquisition. But playing nice with "The System" (e.g. B2B2C distribution, referrals from trad providers, taking reimbursement risk) still has its merits in helping one achieve even more durable scale and unit economics. ⚡ Sequencing of GTM motions matters: if you go "B2C first", you have the gifts of being able to fully control your product roadmap and swiftly acquire users - but it will be more expensive and potentially take longer to acquire them on your own. Going "B2B2C first" means you'll get access to large chunks of users in one fell swoop, but you'll have to pay a "product tax" to appease your B2B partner's requirements, not to mention needing to survive through long enterprise sales cycles. This sequencing choice informs your capital raising strategy in the early days. ⚡ A year ago, everyone was scared to say "AI Doctor", and now everyone is claiming to be building an "AI Doctor"! ⚡ To that end, will healthcare be dominated by an AI Doctor SuperApp as the front door, or will we continue to have fragmentation of apps by use case / condition / demographic? A large portion of consumers who don't have a PCP will find one in the form of an AI Doctor, and the best AI Doctors WILL be SuperApps that connect into a network of specialists and IRL clinical services through a single front door. ⚡ This necessitates a SuperData layer that allows for context sharing across all apps - and not just trad EHR data, but also wearables, genomics, non-traditional biomarker tests, information gleaned through ongoing engagement with AIs, patient-reported outcomes, health plan benefit design data info, etc. The buzz in the room felt a lot like the early versions of the Health 2.0 conference in the late 2000's, BUT with companies that are really working and scaling this time around. Congrats to @ZHTeiger and his organizing team for bringing this community together - it's time to build in consumer health!

New week starts tonight. Make sure your peptide schedule is on track and ready!